Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial - Lotery, A; Sivaprasad, S; OʼConnell, A (Lancet, 2020)